US-based pharmaceutical group Eli Lilly has announced today in a press release that it has completed its strategic review of Elanco Animal Health. After 8 months, the Indianapolis-headquartered company has decided to list an ownership stake of less than 20 percent before the end of the year. Elanco has generated revenues of approximately $3bn in 2017, that is 13% of the group’s revenues. A sale would have fetched Eli Lilly 14 to 16 million dollars, JPMorgan’s analysts say.
(Source: Eli Lilly)